What is the clinical evidence from this study?

Study design: Cross-Sectional. Population: Dysglycaemia (n=300). Intervention: Prediabetes and Type 2 Diabetes Mellitus vs. Normal glucose regulation. Primary outcome: Differences in fasting plasma glucose, HbA1c, fructosamine, and glycated albumin across glucose regulation groups.

What does this research mean for the field?

Fructosamine and glycated albumin levels progressively increase from normal glucose regulation to prediabetes and type 2 diabetes, with glycated albumin providing the greatest statistical separation as a complementary biomarker for recent glycaemic exposure. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate differences in fasting plasma glucose, HbA1c, fructosamine, and glycated albumin across individuals with normal glucose regulation, prediabetes, and type 2 diabetes mellitus.

September 2, 2026Advances in Clinical Medical ResearchOpen Access

A Cross-Sectional Comparative Study of Glycated Albumin and Fructosamine as Complementary Glycaemic Biomarkers Across the Spectrum of Dysglycaemia

View Full Paper

Ask AI

Bookmark

Key result

Glycated albumin rises progressively from prediabetes to T2DM, showing the strongest separation across glycemic stages.

n=300

Population

300 participants aged 18–60 years, divided into controls, prediabetes/impaired glucose homeostasis and…

Design

Cross-sectional

Authors

MManisha JJJaya Jain

Discussion

Member takes

Implication

Glycated albumin and fructosamine show progressive increases from normal glucose tolerance to T2DM, supporting their potential use as complementary markers of recent glycaemic exposure.

Key Points

To evaluate differences in fasting plasma glucose, HbA1c, fructosamine, and glycated albumin across individuals with normal glucose regulation, prediabetes, and type 2 diabetes mellitus.
Conducted a cross-sectional comparative study in India enrolling 300 participants aged 18–60 years divided equally into controls (N=100), prediabetes (N=100), and established type 2 diabetes mellitus (N=100).
Measured fasting plasma glucose, HbA1c, serum fructosamine, and glycated albumin using standard laboratory methods, analyzing group differences using one-way ANOVA and pairwise comparisons.
Both serum fructosamine and glycated albumin demonstrated a progressive, stepwise increase across the spectrum from normal glucose regulation to prediabetes and type 2 diabetes mellitus.
Glycated albumin demonstrated the greatest statistical separation among all evaluated biomarkers across the three clinical cohorts.

Study Design

Type

Cross-Sectional (n=300)

Multicenter

Structured PICO

Population

300 participants aged 18-60 years, divided equally into controls, prediabetes, and established T2DM groups to evaluate glycaemic biomarkers.

Comparator

Comparison between normal glucose regulation, prediabetes, and T2DM groups

Outcome

Difference between fasting plasma glucose (FPG), HbA1c, fructosamine and glycated albumin (GA) between the groupssurrogate

Glycated albumin and fructosamine show progressive increases from normal glucose tolerance to T2DM, supporting their potential use as complementary markers of recent glycaemic exposure.

Cite This Study

Manisha et al. (2026) conducted a cross-sectional in Dysglycaemia (n=300). Prediabetes and Type 2 Diabetes Mellitus vs. Normal glucose regulation was evaluated on Differences in fasting plasma glucose, HbA1c, fructosamine, and glycated albumin across glucose regulation groups. Fructosamine and glycated albumin levels progressively increased from normal glucose regulation to prediabetes and T2DM, with glycated albumin showing the greatest statistical separation.

synapsesocial.com/papers/6a97e2f6c562ede874ec7657 https://doi.org/10.5281/zenodo.22193202

View Full Paper

Ask AI

Bookmark

September 2, 2026Advances in Clinical Medical ResearchOpen Access

A Cross-Sectional Comparative Study of Glycated Albumin and Fructosamine as Complementary Glycaemic Biomarkers Across the Spectrum of Dysglycaemia

View Full Paper

Ask AI

Bookmark

Key result

Glycated albumin rises progressively from prediabetes to T2DM, showing the strongest separation across glycemic stages.

n=300

Population

300 participants aged 18–60 years, divided into controls, prediabetes/impaired glucose homeostasis and…

Design

Cross-sectional

Authors

MManisha JJJaya Jain

Discussion

Member takes

Implication

Glycated albumin and fructosamine show progressive increases from normal glucose tolerance to T2DM, supporting their potential use as complementary markers of recent glycaemic exposure.

Key Points

To evaluate differences in fasting plasma glucose, HbA1c, fructosamine, and glycated albumin across individuals with normal glucose regulation, prediabetes, and type 2 diabetes mellitus.
Conducted a cross-sectional comparative study in India enrolling 300 participants aged 18–60 years divided equally into controls (N=100), prediabetes (N=100), and established type 2 diabetes mellitus (N=100).
Measured fasting plasma glucose, HbA1c, serum fructosamine, and glycated albumin using standard laboratory methods, analyzing group differences using one-way ANOVA and pairwise comparisons.
Both serum fructosamine and glycated albumin demonstrated a progressive, stepwise increase across the spectrum from normal glucose regulation to prediabetes and type 2 diabetes mellitus.
Glycated albumin demonstrated the greatest statistical separation among all evaluated biomarkers across the three clinical cohorts.

Study Design

Type

Cross-Sectional (n=300)

Multicenter

Structured PICO

Population

300 participants aged 18-60 years, divided equally into controls, prediabetes, and established T2DM groups to evaluate glycaemic biomarkers.

Comparator

Comparison between normal glucose regulation, prediabetes, and T2DM groups

Outcome

Difference between fasting plasma glucose (FPG), HbA1c, fructosamine and glycated albumin (GA) between the groupssurrogate

Glycated albumin and fructosamine show progressive increases from normal glucose tolerance to T2DM, supporting their potential use as complementary markers of recent glycaemic exposure.

Cite This Study

synapsesocial.com/papers/6a97e2f6c562ede874ec7657 https://doi.org/10.5281/zenodo.22193202

View Full Paper

Ask AI

Bookmark